GLP-HM4N185BF-100μg / 询价
GLP-HM4N185BF-100μg x 5 / 询价
GLP-HM4N185BF-100μg x 10 / 询价
- 客服电话
- 技术支持
FITC-equivalent Biotinylated GLP-1R Protein-Nanodisc
Recombinant FITC-equivalent Biotinylated GLP-1R Protein-Nanodisc is expressed from HEK293 with His tag and Avi tag at the C-terminus.It contains Met1-Ser463 [Accession | P43220].
The protein has a predicted MW of 85.8 kDa.
Excitation Wavelength: 490 nm
Emission Wavelength: 520 nm
Less than 1EU per μg by the LAL method.
Supplied as 0.22 μm filtered solution in PBS (pH 7.4).
Valid for 12 months from date of receipt when stored at -80°C.
Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Immobilized FITC-equivalent Biotinylated GLP-1R Nanodisc, His Tag at 5μg/ml (100μl/well) on the streptavidin precoated plate (5μg/ml). Dose response curve for Anti-GLP-1R Antibody, hFc Tag with the EC50 of 0.28μg/ml determined by ELISA (QC Test).
Glucagon-like peptide-1 receptor (GLP-1R) is a critical therapeutic target for type 2 diabetes mellitus (T2DM). GLP-1R emerged as an important pharmacological target for addressing T2DM, as it actively contributes to maintaining glucose homeostasis while promoting both β cell proliferation and insulin release. The impact of GLP-1R agonists such as semaglutide extends beyond diabetes control: they play a multifaceted role in regulating blood glucose levels by reducing hunger, moderating food intake, and managing body weight. Notably, GLP-1R agonists inhibit cancer progression in some malignant tumors.
GLP-1 receptor; GLP-1-R; GLP-1R; GLP1R
Ibrahim SS, Ibrahim RS, Arabi B, Brockmueller A, Shakibaei M, Büsselberg D. The effect of GLP-1R agonists on the medical triad of obesity, diabetes, and cancer. Cancer Metastasis Rev. 2024 May 27. doi: 10.1007/s10555-024-10192-9. Epub ahead of print. PMID: 38801466.
